| Private Placement / Financing Transactions
Kyverna: The company raised $152 million of Series B venture funding in a deal led by Bain Capital Life Sciences, GordonMD Global Investments and Northpond Ventures on November 6, 2023. Gilead Sciences, Intellia Therapeutics, Insight Partners, The Argentum Group, LYFE Capital, Vida Ventures, Westlake Village BioPartners, jVEN Capital, RTW Investments, CAM Capital, Hudson Bay Capital Management and HealthCor Management also participated in the round. The company is a developer of cell-based therapeutics designed to offer treatments and cures for autoimmune and inflammatory diseases.
Elucid: The company raised $80 million of Series C venture funding in a deal led by Elevage Medical Technologies on November 9, 2023. The company is a developer of a vascular diagnostic imaging system designed to improve patient outcomes at a reduced cost by applying artificial intelligence.
OrsoBio: The company raised $60 million of Series A venture funding in a deal led by Enavate Sciences and Longitude Capital on November 7, 2023, putting the company’s pre-money valuation at $84 million. Eli Lilly, Samsara BioCapital and Nueva Bio also participated in the round. The company is an operator of a clinical-stage biopharmaceutical company intended to develop therapies for organ dysfunction.
Ascidian: The company raised $40 million of Series A venture funding from Apple Tree Partners (ATP) on November 8, 2023. The company is an operator of a biotechnology business intended to design exon-editing RNA therapeutics to target underlying causes of disease.
Eleos Health: The company raised $40 million of Series B venture funding in a deal led by Menlo Ventures on November 8, 2023. Eight Roads, F-Prime Capital, Samsung NEXT Ventures, lool Ventures, aMoon Fund, Arkin Holdings and ION also participated in the round. The company is a developer of an artificial intelligence-backed voice technology designed to gather insights into behavioral health.
Javara: The company raised $9.4 million of venture funding from undisclosed investors on November 8, 2023. The company provides clinical research access for patients at the point of care by embedding staff and infrastructure into large healthcare organizations, resulting in greater access to cutting-edge innovations.
BRAINBox Solutions: The company raised $7 million of Series B venture funding from undisclosed investors on November 7, 2023. The company is a developer of a medical technology platform designed to offer a multi-modality approach for the diagnosis and prognosis of mild traumatic brain injury.
Okami Medical: The company raised $5 million of venture funding in the form of convertible debt from undisclosed investors on November 9, 2023. The company is a developer of a peripheral embolization device designed to treat cardiovascular disease for the occlusion of peripheral vessels.
Purinomia: The company raised $4.3 million of venture funding in the form of convertible debt from undisclosed investors on November 7, 2023. The company is an operator of a biotechnology business intended to treat cancer, autoimmunity, inflammatory disease, and metabolic syndrome.
Voltron Therapeutics: The company raised $3.5 million of venture funding through a combination of convertible debt and equity from undisclosed investors on November 9, 2023. The company is a developer of a vaccine platform designed to treat cancer and infectious diseases.
Healionics: The company raised $2.7 million of Series B venture funding from undisclosed investors on November 7, 2023. The company is a clinical-stage business addressing the critical need for safer, more reliable means of bloodstream access to perform dialysis in patients with kidney failure.
Valanx Biotech: The company raised EUR 2.3 million of venture funding in a deal led by SkyGene on November 7, 2023. SOSV, Tecnet Equity, and IST cube also participated in the round. The company is a developer of a site-specific protein conjugation platform designed to develop fast and cost-efficient protein-drug-conjugates.
Irazu Oncology: The company is in the process of raising venture funding in the form of convertible debt financing from undisclosed investors as of November 7, 2023. The company is an operator of a biotechnology platform intended to improve clinical outcomes for cancer patients.
Terray Therapeutics: The company raised an undisclosed amount of venture funding from nVentures, John Maraganore and Bassil Dahiyat on November 9, 2023. The company is an operator of a biotechnology business intended to provide chemical datasets that facilitate drug discovery.
Zeta Surgical: The company raised an undisclosed amount of venture funding from Artesian Capital Management, Innospark Ventures and TSVC on November 9, 2023. ParticleX, Y Combinator and Valera Capital also participated in the round. The company is a developer of surgical navigation and robotics tools designed to bring quality image guidance into a wider range of medical procedures.
|
